All Updates

All Updates

icon
Filter
Partnerships
Takeda and AC Immune partner to develop immunotherapy for Alzheimer's disease
Precision Medicine
May 13, 2024
Last week:
Partnerships
Geographic expansion
Lemonade partners with Homesite to expand home insurance services
InsurTech: Personal Lines
Jun 14, 2024
Funding
BayaniPay raises USD 3 million in seed funding to expand payment solutions
Neobanks
Jun 14, 2024
Partnerships
Carbonfuture and Swiss Re partner for long-term carbon removal through biochar
Carbon Management Software
Jun 13, 2024
Funding
Sidekick raises GBP 8.5 million in seed and debt funding to support expansion
Retail Trading Infrastructure
Jun 13, 2024
Partnerships
Climatiq and Epicor partner to reduce CO2 emissions in supply chains
Carbon Management Software
Jun 13, 2024
Product updates
EHang's pilotless eVTOL aircraft concludes first flight launch in Saudi Arabia
Passenger eVTOL Aircraft
Jun 13, 2024
Partnerships
Skyports partners with Unified Aviation to accelerate global network release
Passenger eVTOL Aircraft
Jun 13, 2024
Partnerships
Industry news
USSF chooses Blue Origin, SpaceX, and ULA for ~USD 5.6 billion Pentagon launch contracts
Space Travel and Exploration Tech
Jun 13, 2024
Funding
AnyCreek raises USD 1.8 million in seed funding to enhance platform and expand into new markets
Travel Tech
Jun 13, 2024
Funding
Zeta Labs raises USD 2.9 million in pre-seed funding to develop autonomous AI agent
Generative AI Applications
Jun 13, 2024
Precision Medicine

Precision Medicine

May 13, 2024

Takeda and AC Immune partner to develop immunotherapy for Alzheimer's disease

Partnerships

  • Takeda and AC Immune have entered an exclusive global licensing agreement for AC Immune's Alzheimer's treatment, ACI-24.060. The treatment targets toxic forms of amyloid beta, stimulating an antibody response that inhibits plaque formation in the brain to treat Alzheimer's disease.

  • As per the agreement, AC Immune will receive an upfront payment of USD 100 million, approximately USD 2.1 billion in development, commercial, and sales-related milestone payments, and tiered double-digit royalties on worldwide net sales after the commercialization of the product. 

  • AC Immune is a Switzerland-based biopharmaceutical company specializing in developing therapeutic and diagnostic products aimed at neurodegenerative diseases, often linked to protein misfolding. The company uses two proprietary technology platforms, SupraAntigen and Morphomer, to develop biologics, small molecules, and vaccines. AC Immune’s key drug candidates include Crenezumab, designed to slow the progression of Alzheimer's disease, and Semorinemab, targeting Tau proteins in Alzheimer's patients​.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.